ARTIVA BIOTHERAPEUTICS INC Stock Price, News & Analysis

Artiva Biotherapeutics (NASDAQ: ARTV) announced promising longer-term Phase 1/2 data for AlloNK® in combination with rituximab for treating B-cell non-Hodgkin lymphoma (B-NHL). The treatment showed a 64% complete response rate (9/14 patients) in heavily pretreated patients naive to CAR-T therapy. The median duration of response has not been reached and extends beyond 19.4 months, comparable to approved auto-CAR-T therapies. The treatment demonstrated a well-tolerated safety profile with no reported cases of cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease. Common side effects were primarily hematologic, including neutropenia (84%), leukopenia (82%), and lymphopenia (71%). The results suggest potential applications for treating autoimmune diseases through enhanced B-cell depletion in outpatient community settings.

Artiva Biotherapeutics (NASDAQ: ARTV) reported its Q1 2025 financial results and business updates. The company announced IND clearance and initiation of a global basket trial exploring AlloNK® + rituximab in multiple autoimmune conditions, marking the first allogeneic cell therapy trial for rheumatoid arthritis and Sjögren's disease in the U.S. The company ended Q1 2025 with $166.0 million in cash, extending runway into Q2 2027.

Key financial metrics include R&D expenses of $17.1 million (up from $11.2M in Q1 2024), G&A expenses of $5.1 million (up from $3.6M), and a net loss of $20.3 million (increased from $14.0M). The company's B-NHL trial data showed promising results comparable to approved auto-CAR-T therapies. Initial safety and translational data are expected by year-end 2025, with clinical response data in the lead indication planned for 1H2026.

Artiva Biotherapeutics announced new data presentations for their AlloNK® cell therapy at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans this May.

Key highlights:

• New longer-term Phase 1/2 data shows promising results for AlloNK® combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma
• Treatment demonstrated prolonged response duration, deep B-cell depletion, and well-tolerated safety profile
• Results support AlloNK's potential for treating B-cell driven diseases in community settings

Two poster presentations are scheduled:

• May 13: AlloNK® Cell Therapy ± Rituximab in Patients with Non-Hodgkin Lymphoma
• May 15: AlloNK manufacturing process scalability and consistency

The presentations highlight Artiva's progress in developing accessible cell therapies for autoimmune diseases and cancers. Abstracts are available on the ASGCT website, with poster copies to be shared on Artiva's website after the presentations.

Artiva Biotherapeutics (ARTV) has appointed Dr. Subhashis Banerjee as Chief Medical Officer, succeeding Dr. Thorsten Graef who will continue as a strategic advisor. Dr. Banerjee brings over 20 years of clinical development experience in autoimmune diseases, previously serving as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb and SVP of Clinical Development at VYNE Therapeutics.

The appointment strengthens Artiva's focus on developing their AlloNK® program for B-cell driven autoimmune diseases. Dr. Banerjee's expertise includes development of blockbuster therapies like Humira®, Taltz®, Orencia®, and Sotyktu®. The company has also expanded its development team with key appointments including David Moriarty as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics.

Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's management will deliver a presentation on Monday, April 7, 2025, at 11:00 a.m. EDT. The management team will also be available for meetings with registered conference investors.

A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section of Artivabio.com. The webcast recording will remain available for 90 days following the event.

Artiva Biotherapeutics (NASDAQ: ARTV) has reported its full year 2024 financial results and business updates. The company ended 2024 with $185.4 million in cash and investments, expected to fund operations through 2026. This includes $179.0 million raised from their July 2024 IPO.

Key financial metrics show a net loss of $65.4 million for 2024, compared to a net income of $28.7 million in 2023. R&D expenses remained stable at $50.3 million, while G&A expenses increased to $17.2 million from $13.9 million in 2023. Collaboration revenue dropped to zero from $32.9 million in 2023.

The company expects to share initial data for AlloNK® from their autoimmune program in H1 2025, along with updated clinical data from their Phase 1/2 trial exploring AlloNK + rituximab in NHL. Artiva has strengthened its leadership team with expertise in cell therapy and autoimmune disease, including the appointment of Dr. Dan Baker to the Board of Directors.

Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 5, 2025, at 2:30 p.m. EST in Boston, MA.

The management team will be available for in-person meetings with registered conference attendees. A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section on Artivabio.com, with the replay remaining available for 90 days after the event.

Artiva Biotherapeutics (ARTV) has appointed Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker, currently interim Chief Development Officer at Cue Biopharma, brings over 20 years of pharmaceutical industry experience, including a 19-year tenure at Johnson & Johnson where he led the development of major immunology drugs like Remicade, Simponi, and Stelara, which achieved over $20 billion in peak sales.

Previously, Dr. Baker served as CEO and Founder of Kira Biotech and Executive Director on Galapagos Therapeutics' board. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania, with extensive medical training and academic experience in Rheumatology.

Artiva Biotherapeutics (ARTV) reported Q3 2024 financial results, highlighting a strong cash position of $199.6 million as of September 30, 2024, expected to fund operations through 2026. The company completed an upsized $179.0 million IPO in July 2024. Q3 showed a net loss of $17.5 million compared to net income of $11.3 million in Q3 2023. R&D expenses were $13.5 million, while G&A expenses increased to $4.8 million. The company expanded its Board with Dr. Alison Moore and expects initial data for AlloNK® in autoimmune indications in H1 2025.